|
|
|
市場調查報告書
全球癌症治療和生物療法市場:第4版
The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition
|
全球癌症治療和生物療法市場:第4版 是由出版商Kalorama Information在2012年01月所出版的。
這份英文市場調查報告書包含245 Pages 價格從美金3500起跳。
本報告以癌症治療為焦點，彙整現在上市的治療藥物及開發後期階段的藥物概要及市場收益，各產品的銷售額等資料彙整，參與企業簡介，為您概述為以下內容。
第1卷 摘要整理
第2章 簡介
- 癌症是什麼
- 癌症治療市場歷史和成長
- 產業結構
- 人口統計
- 壽命和癌症
- 癌症詳細內容
第3章 化療
第4章 荷爾蒙療法
- 概要
- 產品概要與案例
- 皮質類固醇
- 荷爾蒙作用藥與拮抗劑
- 芳香酶抑制劑
- 雌激素受體調整
- 市場規模與成長
- 競爭分析
第5章 生物療法
- 概要
- 產品概要與案例
- 單株抗體
- 白細胞介素/干擾素
- 酪氨酸激酶抑製劑
- 其他生物療法
- 放射免疫療法
- 市場規模與成長
- 競爭分析
第6章 全球癌症治療:整體市場規模與預測
第7章 影響癌症市場的問題與趨勢
- 簡介
- 保險和報銷問題
- 癌症治療成本
- 個體化醫療
- 癌症標靶治療
- 醫藥基因學
- 合作，收購，授權契約
- 病人報告結果
- 酒精的影響
- 健康的生活方式可以預防癌症
- 癌症趨勢
- 行銷和銷售趨勢
- 各地區趨勢
- 成人臨床實驗參與計劃
- 開發後期藥物趨勢
- 最近的NDA活動
- 新核准
第8章 企業簡介
- 簡介
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
第9章 競爭企業名錄
圖表
Abstract
This Kalorama Information report - The World Market for Cancer Therapeutics
and Biotherapeutics, 4th Edition - focuses on several segments for cancer
treatment including:
- Chemotherapy, including -subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each
- Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS-Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.
- Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy-Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux
One of the most promising new approaches in modern cancer treatment is
immunotherapy or biotherapy, the development of methods to augment and enhance
the body' s natural tendency to defend itself against malignant tumors without
damaging healthy tissue. The report devotes particular attention to these new
therapies.
This report, Kalorama' s fourth complete research effort into the oncology
treatments market in the past ten years, provides market size information for
the various types of cancers including the following:
- Bladder
- Breast
- Cervical
- Colorectal
- Esophageal
- Head/Neck
- Kidney
- Leukemia
- Liver
- Lung
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian
- Pancreatic
- Prostate
- Stomach
The report covers both currently marketed and late stage development cancer
products. Revenues for each current market segment were generated using dollar
and unit sales for each product.
The report includes statistical information for cancers by type worldwide,
with special emphasis on the U.S. market. Specifically, cancers where there
are current products available or are in development and/or have significant
incidence/mortality rates are profiled. The market segments provide an
overview, description of products on the market, leading product sales, market
estimates and forecasts, and competitive analysis of leading providers. The
report also includes a list of products in development and current issues and
trends affecting the industry.
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information. For the purpose of this study Kalorama Information
conducted interviews with key industry officials, consultants, health care
providers, and government personnel. These sources were the primary basis in
gathering information specifically relating to revenue and market share data
presented in this report. Specific interviews with pharmaceutical company
representatives included marketing directors, division managers, and product
representatives.
As part of its coverage, the report looks at the following trends:
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol' s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- Outlook for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends (US, Europe, Japan)
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
All market data pertains to the world market at the manufacturers' level. The
base year for data was 2010. Historical data was provided for the years 2005
through 2009, with forecast data provided for 2011 through 2015. Compound
annual growth rates (CAGRs) are provided for the 2005-2010, 2010-2015 and
2005-2015 periods for each industry segment covered. Competitive analysis is
provided for the year 2010. The forecasted market analysis for 2010-2015 was
based on probability of approval and sales of products in late stage
development, competitive trends, product marketing, and demographic trends.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: At A Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Aging Population
- Life Expectancy and Cancer
- Life Expectancy
- Birth Rates
- Description of Cancers
- Bladder Cancer
- Brain Cancer
- Glioblastoma
- Neuroblastoma
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
- Overview
- Product Descriptions and Examples
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
- Overview
- Product Descriptions and Examples
- Corticosteroids
- Hormone Agonists and Antagonists
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS
- Overview
- Product Descriptions and Examples
- Monoclonal Antibodie
- Interleukins/Interferons
- Tyrisoine Kinase Inhibitors
- Other Biotherapeutics
- Radioimmunotherapy
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Overview
- Total Market Size and Forecast
- Geographical Market Distribution
- Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Introduction
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol' s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Obesity in the U.S.
- U.S. Obesity Rates Differ Among Ethnic Groups
- Outlook for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends
- United States
- Europe
- Japan
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
- Significant Developments
- Alpharadin
- Afatinib
- Axitinib
- Bosutinib
- Brentuximab
- Carfilzomib
- Crizotinib
- Erwinaze
- Exelbine
- Motesanib
- Omnitarg
- Regorafenib
- Ridaforolimus
- Zaltrap
- Recent NDA Activity
- New Approvals
CHAPTER EIGHT: CORPORATE PROFILES
- Introduction
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
APPENDIX: MAJOR COMPETITOR DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: World Cancer Market
- Table 1-2: Market by Product Type (Chemotherapy, Hormone Therapy,
Biotherapeutics), 2005-2015
- Figure 1-1: World Cancer Market, Market by Product Type (Chemotherapy,
Hormone Therapy, Biotherapeutics), 2005-2015
- Figure 1-2: World Cancer Market, Market by Product Type and Percent Market
Share, 2010
CHAPTER TWO: INTRODUCTION
- Table 2-1: Viruses Associated with Cancer in Humans
- Figure 2-1: Approved Cancer Therapies in the United States by Primary
Indication
- Table 2-2: World Cancer Incidence by Selected Types of Cancer, 2010 and
2020, (Lung,Breast, Colon/ Rectum, Stomach, Liver, Prostate, Cervical,
Ovarian, Lymphoma, Pancreatic, Melanoma)
- Figure 2-2: Estimated and Projected World Cancer Incidence by Selected
Types of Cancer, 2010 and 2020
- Table 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Figure 2-3: Total Cancer Incidence by Sex and Country(Canada, China,
France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom,
United States), 2010 Estimates
- Table 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010 - 2050
- Figure 2-4: World Population by Selected Geographical Region(Africa, Asia,
Europe, North America, Oceania, South America, World), 2010-2050
- Table 2-5: Percent Population Over 65 by Year and Region, 2010-2050
- Figure 2-5: Estimated World Population by Age, 2010 and 2050
- Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2009
- Figure 2-6: Average Life Expectancy in Years by Country 1980 and 2009
- Figure 2-7: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
- Figure 2-8: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2006
- Table 2-7: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Figure 2-9: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
- Table 2-9: Types of Leukemia
- Table 2-9: Types of Primary Lung Cancer
- Table 2-10: Classification of Non-Hodgkin' s Lymphomas
- Table 2-11: Malignant Conditions of the Skin
CHAPTER THREE: CHEMOTHERAPY
- Table 3-1: Leading Products, 2010
- Table 3-2: World Chemotherapy Market, 2005-2015
- Figure 3-1: World Chemotherapy Market, 2005-2015
- Table 3-3: World Chemotherapy Market, Sales by Drug Classification,
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives) 2010
- Figure 3-2: World Chemotherapy Market by Drug Classification, (Alkylating
Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives)
- Table 3-4: World Chemotherapy Market, Sales by Drug Classification
(Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives),
Estimated 2010)
- Figure 3-3: World Chemotherapy Market by Drug Classification (Alkylating
Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2015
- Figure 3-4: World Chemotherapy Current Market by Region (US, EU, Japan,
ROW)
- Figure 3-5: World Chemotherapy Market by Region 2015 (US, EU, Japan, ROW)
- Table 3-5: World Chemotherapy Market Type by Cancer Type (Lung, Breast,
Colon, Brain, Ovarian, Other Total)
- Figure 3-6: World Chemotherapy Market by Cancer Type (Lung, Breast, Colon,
Brain, Ovarian, Other Total)
- Table 3-6: World Chemotherapy Market, Leading Suppliers Shares by Market
Revenues, 2010
- Figure 3-7: World Chemotherapy Market, Leading Suppliers Market Share, 2010
CHAPTER FOUR: HORMONE THERAPY
- Table 4-1: Leading Products, 2010
- Table 4-2: World Hormone Therapy Market, 2005-2015
- Figure 4-1: World Hormone Therapy Market, 2005-2015
- Table 4-3: World Hormone Therapy Market, Sales by Drug Classification (
Corticosteroids, Hormone agonists/ Antagonists, Aromatase Inhibitors, SERMs),
2010
- Figure 4-2: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs)
and Percent Market Share, 2010
- Table 4-4: World Hormone Therapy Market, Sales by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors ,
SERMs), Estimated 2015
- Figure 4-3: World Hormone Therapy Market, Market by Drug Classification
(Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs)
and Percent Market Share, 2015
- Figure 4-4: World Hormone Therapy Current Market by Region (US, EU, Japan,
ROW)
- Figure 4-5: World Hormone Therapy Market by Region 2015 (US, EU, Japan,
ROW)
- Table 4-5: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Figure 4-6: World Hormone Therapy Market by Cancer Type (Breast, Prostate,
Other)
- Table 4-6: World Hormone Therapy Market, Leading Suppliers Shares by
Market Revenues, 2010
- Figure 4-7: World Hormone Therapy Market, Leading Suppliers Market Share,
2010
CHAPTER FIVE: BIOTHERAPEUTICS
- Table 5-1: Leading Biopharmaceutical Cancer Treatment Products (Brand
Name, Generic Name, Manufacturer/ Marketer, Common Uses, Annual Sales ), 2010
- Table 5-2: World Cancer Biotherapeutics Market, 2005-2015
- Figure 5-1: World Cancer Biotherapeutics Market, 2005-2015
- Table 5-3: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), 2010
- Figure 5-2: World Biotherapeutics Market by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics)
- Table 5-4: World Biotherapeutics Market, Sales by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), Estimated 2015
- Figure 5-3: World Biotherapeutics Market by Drug Classification
(Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors,
Other Biotherapeutics), Estimated 2015
- Figure 5-4: World Cancer Biotherapeutics Market by Region (US, EU, Japan,
ROW)
- Figure 5-5: World Cancer Biotherapeutics Market by Region (US, EU, Japan,
ROW) , Estimated 2015
- Table 5-5: World Cancer Biotherapeutics Market by Cancer Type (Colon,
Breast, Lymphoma, Leukemia, Others)
- Figure 5-6: World Cancer Biotherapeutics Market by Cancer Type(Colon,
Breast, Lymphoma, Leukemia, Others)
- Table 5-6: World Biotherapeutics Market, Leading Suppliers Shares by
Market Revenues, 2010
- Figure 5-7: World Cancer Biotherapeutics Market, Leading Suppliers Market
Share, 2010
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Table 6-1: World Cancer Market, Market by Product Type, 2005-2015
- Figure 6-1: World Cancer Market, Market by Product Type Revenues, 2005-2015
- Figure 6-2: World Cancer Market, Market by Product Type and Percent Market
Share, 2010
- Figure 6-3: World Cancer Market, Market by Product Type and Percent Market
Share, 2015
- Table 6-2: World Cancer Market, Leading Suppliers' Shares by Market
Revenues, 2010
- Figure 6-5: World Cancer Market, Leading Suppliers' Market Share, 2010
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Table 7-1: Obesity Rates by U.S. State, 2009
- Table 7-2: Select Products in Development by Development Phase
- Figure 7-1: Late Stage Cancer Compounds in Development for Major
Indications, Distribution Estimates
- Table 7-3: Recent NDA Activity: January 2011-July 2011
- Table 7-4: Select New Approvals (NCE, Indications, Dosage, Formulations)
,2010-11
CHAPTER EIGHT: CORPORATE PROFILES
- Figure 8-1: Late stage Cancer Therapies in Development for Leading
Companies
酪胺酸激酶抑制劑在癌治療藥的銷售額擴大市占率
2011年10月24日
Global Information, Inc.已開始銷售Kalorama Information所發行的報告書「The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition (全球癌症治療和生物療法市場:第4版)」
名叫Gleevac和Nexavar的酪胺酸激酶抑制劑，是在癌治療市場最迅速成長的領域，牽引許多製藥公司的成果。醫療市場的調查公司Kalorama Information推定，2010年全球癌治療市場為544億美元規模。
Kalorama Information的Bruce Carlson述說：「過去5年癌的生物療法急劇成長，從荷爾蒙及化學療法的銷售額中奪走市占率。」。「而且，在此領域，酪胺酸激酶抑制劑的有效性已很明顯，銷售額迅速成長。」
受容體酪胺酸激酶抑制劑的突然變異，已成為細胞增殖及人類生病的原因。Iressa和Tarceva、Tykerb、Sprycel、Tasigna、Sutent 及此領域稱作Votrient的最新治療藥，阻礙了受容體的功能，抑制癌的異常細胞增殖。聚焦於此最新治療法研發出的治療藥之銷售額，將繼續平穩。Kalorama Information分析，過去5年酪胺酸激酶抑制劑比其他任何的癌治療藥更迅速以約26.7％成長。
本報告書中敘述，癌發生率上升，尤其是50歲以上者增加，對癌治療的所有側面可能有重大影響。然對許多的癌來說，依然存在有效果治療之重大未被滿足的需求。例如，肺癌為其一例，患者生存期間從發現到死亡不滿5年。本報告書亦介紹正在開發的新治療法。
|
 |
